Grifols, FTC Ink Deal To Allow $3.4B Talecris Tie-Up

Law360, New York (May 2, 2011, 3:33 PM EDT) -- Grifols SA said Monday it had reached a tentative agreement with federal antitrust regulators that should allow its planned $3.4 billion purchase of rival Talecris Biotherapeutics Holdings Corp. to move forward once certain blood plasma assets are sold off.

Barcelona-based Grifols said it had signed a consent agreement with Federal Trade Commission staff that involves selling two blood plasma collection centers, among other assets, and entering into commercial, lease and manufacturing agreements with the Italian company Kedrion SpA.

“Neither the consent agreement nor the agreements signed...
To view the full article, register now.